FivePrime Appoints Julia Gregory Chief Executive Officer and Member of Board of Directors SAN FRANCISCO, California – June 9, 2009 . Five Prime Therapeutics, Inc. today announced the appointment of Julia P. Gregory as President and Chief Executive Officer and a member of the Company’s board of
FivePrime Initiates Phase 1 Clinical Trials of FP-1039 in Patients with Advanced Cancers SAN FRANCISCO, California – September 8, 2008 . Five Prime Therapeutics, Inc today announced the first patient has been enrolled in a Phase I clinical trial of its investigational protein therapeutic, FP-1039,
FivePrime and Pfizer enter Oncology and Diabetes Collaboration SAN FRANCISCO, California – May 20, 2008 . Five Prime Therapeutics, Inc. and Pfizer Inc (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement.
FivePrime Reports Discovery of IL-34 SAN FRANCISCO, California – May 8, 2008. In this week’s edition of the journal Science, researchers at Five Prime Therapeutics, Inc. report the discovery of Interleukin‐34, a novel cytokine, as well as the identification of an IL‐34 receptor.
FivePrime achieves target discovery milestone with Boehringer Ingelheim SAN FRANCISCO, California - October 01, 2007 , Five Prime Therapeutics, Inc., the protein therapeutics discovery and development company, today announced that it has successfully achieved a target discovery milestone in its
FivePrime enters Osteoarthritis and Pulmonary Fibrosis Collaboration with Centocor San Francisco, California – January 3, 2007 . Five Prime Therapeutics, Inc. today announced a worldwide collaborative research and license agreement with Centocor Research and Development Inc.
Mark McDade to join FivePrime Board of Directors San Francisco - Five Prime Therapeutics, Inc. today announced that it has appointed Mark McDade, CEO of PDL BioPharma, Inc, to the FivePrime Board of Directors. “We are delighted to have Mark join our Board”, said Lewis T.
FivePrime and Boehringer Ingelhein Initiate Rheumatoid Arthritis Collaboration San Francisco - Five Prime Therapeutics, Inc. announced today to have entered into a two year collaborative research and license agreement with Boehringer Ingelheim to discover novel therapeutic products to treat
Biosite and FivePrime Announce Antibody Collaboration SAN DIEGO and SAN FRANCISCO—Biosite® Incorporated (Nasdaq: BSTE) and Five Prime Therapeutics, Inc. have entered into a collaboration for the evaluation of disease targets for potential commercialization of diagnostic and therapeutic products.